MK-2206
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colon Cancer
Conditions
Colon Cancer, Rectal Cancer
Trial Timeline
Aug 1, 2010 → Aug 1, 2011
NCT ID
NCT01186705About MK-2206
MK-2206 is a phase 2 stage product being developed by Merck for Colon Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01186705. Target conditions include Colon Cancer, Rectal Cancer.
What happened to similar drugs?
4 of 14 similar drugs in Colon Cancer were approved
Approved (4) Terminated (5) Active (6)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01249105 | Phase 2 | Withdrawn |
| NCT01186705 | Phase 2 | Terminated |
| NCT01169649 | Phase 2 | Completed |
| NCT00670488 | Phase 1 | Completed |
Competing Products
20 competing products in Colon Cancer